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Abstract
Angiogenesis is the result of the combined activity of the tumor microenvironment and signaling molecules. The
angiogenic switch is represented as an imbalance between pro- and anti-angiogenic factors and is a rate-limiting step in the
development of tumors. Eph receptor tyrosine kinases and their membrane-anchored ligands, known as ephrins, constitute
the largest receptor tyrosine kinase (RTK) subfamily and are considered a major family of pro-angiogenic RTKs. Ewing
sarcoma (EWS) is a highly aggressive bone and soft tissue tumor affecting children and young adults. As other solid tumors,
EWS are reliant on a functional vascular network for the delivery of nutrients and oxygen and for the removal of waste.
Based on the biological roles of EphA2 in promoting angiogenesis, we explored the functional role of this receptor and its
relationship with caveolin-1 (CAV1) in EWS angiogenesis. We demonstrated that lack of CAV1 results in a significant
reduction in micro vascular density (MVD) on 3 different in vivo models. In vitro, this phenomenon correlated with
inactivation of EphA2 receptor, lack of AKT response and downregulation of bFGF. We also demonstrated that secreted
bFGF from EWS cells acted as chemoattractant for endothelial cells. Furthermore, interaction between EphA2 and CAV1 was
necessary for the right localization and signaling of the receptor to produce bFGF through AKT and promote migration of
endothelial cells. Finally, introduction of a dominant-negative form of EphA2 into EWS cells mostly reproduced the effects
occurred by CAV1 silencing, strongly suggesting that the axis EphA2-CAV1 participates in the promotion of endothelial cell
migration toward the tumors favoring EWS angiogenesis.
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Introduction
Caveolin-1 (CAV1) is an integral membrane protein involved in
caveolae biogenesis, cholesterol homeostasis, intracellular traffick-
ing and signal transduction, amongst other functions. The precise
role of caveolin-1 in tumorigenesis and whether the protein acts as
a tumor suppressor or as an oncogene seems to be cell type and
context-dependent [1]. Recently, we identified CAV1 as a
metastasis-associated gene that is a transcriptional target of
EWS/FLI1 as well as an important determinant of Ewing sarcoma
(EWS) malignant phenotype and tumorigenicity [2]. CAV1 has
been shown to generate autocrine and paracrine positive feedback
loops by increasing several factors mRNA stability, leading to
increased levels of these proteins and increased pro-angiogenic
activities [3]. However, this potential role has not been explored
yet in EWS.
The process of tumor neovascularization proceeds through the
combined output of inductive signals from the entire cellular
constituency of the tumor. The concept of the ‘‘angiogenic
switch,’’ whereby tumors acquire the ability to grow exponentially
and disseminate beyond their primary site, is one of the central
components in our understanding of cancer [4]. The new vessels
not only help to meet the growing metabolic demands of the
tumor by supplying additional nutrients, but also provide potential
routes for tumor dissemination and metastasis [5]. During the
initial phase, genetic changes and local hypoxia in tumors
contribute to increased secretion of soluble angiogenic factors by
tumor cells, stromal cells and inflammatory cells. These angiogenic
factors include: vascular endothelial growth factor (VEGF), basic
fibroblast growth factor (bFGF), platelet derived growth factor
(PDGF), epidermal growth factor (EGF), insulin-like growth factor
(IGF), placental growth factor (PlGF), and others. All these factors
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promote the sprouting of new vessels from nearby existing vessels
[6].
Eph receptor tyrosine kinases and their membrane-anchored
ligands, known as ephrins, constitute the largest receptor tyrosine
kinase (RTK) subfamily, including at least 16 receptors and 9
ligands in vertebrates [7]. Based on their binding preference to one
or the other class of ephrins, Eph receptors have been subdivided
into two subclasses, EphA and EphB. Eph receptors have diverse
activities, including widespread effects on the intercellular
junctions, cell shape, cell-substrate adhesion, cell movement and
angiogenesis [8]. Moreover, the ephrin family is considered to be a
major family of pro-angiogenic RTKs. Of these molecules, the
EphA2 receptor, initially linked with neuronal migration during
embryogenesis [9], is the most thoroughly studied with regard to
its role in angiogenesis, and it has been implicated in responses
such as endothelial cell migration and vascular assembly as well as
regulation of epithelial cell junctions [10].
EWS is a highly aggressive bone and soft tissue tumor affecting
children and young adults [11]. Patients most commonly die as a
result of the development of metastases [12]. Abnormal vessel
growth and function are hallmarks of cancer disease, and they
contribute to metastasis and disease progression [13]. EWS, like
other solid tumors, are reliant on a functional vascular network for
the delivery of nutrients and oxygen and for the removal of waste
[14]. Upon clinical presentation, Ewing tumors are highly
hemorrhagic and harbor large and friable vessels. Therefore,
defining the molecular mechanisms that direct blood vessel
formation in EWS is key identifying new therapeutic targets that
might prevent vascular development and metastasis.
Based on the biological roles of EphA2 in promoting
angiogenesis [15], we explored the functional role of this receptor
and its relationship with CAV1 in EWS angiogenesis. We
demonstrated that lack of CAV1 results in a significant reduction
in micro vascular density (MVD) in 3 different in vivo models. In
vitro, this phenomenon correlated with inactivation of EphA2
receptor and downregulation of bFGF. We also demonstrated that
secreted bFGF from EWS cells acted as chemoattractant for
endothelial cells. Furthermore, interaction between EphA2 and
CAV1 was necessary for the right localization and signaling of the
receptor to produce bFGF through AKT. Finally, introduction of
a dominant-negative form of EphA2 into EWS cells reproduced
most of the effects occurred by CAV1 silencing, strongly
suggesting that the axis EphA2-CAV1 participates in the
promotion of endothelial cell migration toward the tumors
favoring EWS angiogenesis.
Results
Growth Reduction in CAV1 Knocked down Xenografts is
a Consequence of Impaired Angiogenesis
To further explore the mechanism by which CAV1 promotes
tumor growth in EWS, we knocked down CAV1 expression in
RDES, TC71 and SKES1 cells (Figure 1A) as previously described
[2,16]. In agreement with previous results [2], CAV1 silencing
resulted in significant tumor growth reduction in all three models
(P#0.05) (Figure 1B). H&E staining showed a reduced number of
vessels and a major incidence of necrosis in tumor sections from
CAV1 knocked down cells (Figure 1C). Moreover, CD31 staining
showed a significant reduction on MVD (P#0.05) in CAV1
knocked down tumors (Figure 1D).
Tumor cells secrete factors that promote the growth and the
migration of endothelial cells to the tumor [17]. Conditioned
media (CM) from CAV1 knocked down cells showed significant
reduced capability to promote migration of endothelial cells
(P#0.05) with no changes in proliferation (Figure 2A–B).
Moreover, immunofluorescence of phospho-FAK in endothelial
cells grown with CM from control cells showed its localization on
sprouts. In contrast, in endothelial cells grown with CM from
CAV1 knocked down cells phosphorylated FAK appeared in a
more perinuclear location (Figure 2C). Analysis of FAK expression
showed higher levels of cleaved FAK in those cells grown with CM
from control cells (Figure 2D). These results suggested that CM
from CAV1 knocked down cells had reduced levels or lack of a
factor that promoted migration of endothelial cells. In order to
ascertain which factor or factors may be responsible for such
activity, we explored by RT-PCR the expression of several pro-
angiogenic factors in different EWS cell lines (Figure S1). Of all
pro-angiogenic factors tested, bFGF was the only one reduced
upon CAV1 knock down in all three models (Figure 3A and Figure
S2). Accordingly, in the TC71 model, protein expression was also
reduced from cell extracts and in CM (Figure 3B). Furthermore,
CM from parental TC71 cells in the presence of a neutralizing
antibody against bFGF showed similar reduced capability
promoting endothelial cell migration than CAV1 knocked down
cells (Figure 3C). Addition of recombinant bFGF to CM from
CAV1 knocked down cells restored endothelial cell migration
(Figure 3C) strongly suggesting that bFGF secreted from EWS cells
promotes endothelial cell migration.
Proper Localization and Signaling of EphA2 Receptor
Depends on CAV1 Interaction
CAV1 has been shown to function as an activator of EphA2
signaling in endothelial cells [18]. Thus, we sought whether
EphA2 was expressed in EWS. As shown in figure 4A, EphA2
receptor was widely expressed among EWS cell lines. Also,
immunohistochemical analysis of a panel of 28 patients showed
high expression of EphA2 in all samples. Moreover, although
EWS cells lines showed expression of other members of the Eph
receptor family (data not shown), their expression in tumor
samples was not observed (Figure S3). Interestingly, CAV1
silencing resulted in a slight, if any, decrease of EphA2 protein
expression (Figure 4B), a clear decrease on its phosphorylation
(Figure 4C) and a displacement of the receptor from the
membrane to the cytosolic fraction of the cell (Figure 4D). Of
note, in EWS cells EphA2 receptor was shown to be constitutively
phosphorylated (Figure 4C) suggesting that EWS cells express its
main ligand ephrin-A1. As shown in Figure S4, EWS cells indeed
express this ligand. Based on the results exposed above we
explored the possibility that CAV1 was promoting localization and
signaling of EphA2 through direct interaction in EWS cells.
Consequently, cell lysate from the RDES model was subjected to
immunoprecipitation using specific antibodies. As seen in
Figure 5A, EphA2 was present in the CAV1 immunoprecipitated
samples and vice versa, suggesting that CAV1 interacts with
EphA2. No fusion proteins were detected in control immunopre-
cipitation reactions performed with IgG antibodies (Figure 5A).
Accordingly, confocal microscopy analysis showed co-localization
of both proteins in the plasma membrane of RDES cells
(Figure 5B) and xenografts (Figure S5). In order to further
demonstrate the implication of CAV1 in EphA2 signaling we
stimulated cells from the RDES and TC71 models with a soluble
activating form of ephrin-A1 (ephrin-A1 Fc). Contrary to CAV1
knocked down cells, addition of ephrin-A1 to controls resulted in
tyrosine hyper-phosphorylation of EphA2 (Figure 6A). Interest-
ingly, after ephrin stimulation no activation of ERKs was observed
in the whole model. However, it resulted in activation of AKT
(Figure 6B) and overexpression of bFGF (Figure 6D) in control
cells but not in CAV1 knocked down cells, suggesting that the
CAV1-EphA2 Signaling and Angiogenesis in EWS
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Figure 1. CAV1 silencing reduces vascularization in EWS. A. Immunoblot showing substantially reduced CAV1 levels in selected clones of
RDES, TC71 and SKES1 cells stably expressing a CAV1 shRNA compared with untransfected cells and cells transfected with an empty vector. b-Actin
was used as loading control. B. Mice xenograft volumes comparing tumors from grouped control cells (parental n = 5; empty vector n = 5) and 2 CAV1
knocked-down cells (n = 5 for every clone); bars, SD (*P#0.05) C. Hematoxylin and Eosin (H&E) staining from corresponding paraffin-embedded
tumors. Asterisks indicate necrotic lakes Scale bar, 50 mm. D. CD31 immunohistochemistry detecting positive blood vessels in paraffin-embedded
tumors. Arrows indicate blood vessel staining Scale bar, 50 mm. Graph shows MVD comparing all three models and showing the constant reduction
of blood vessels in CAV1 knocked-down cells; bars, SD (*P#0.05).
doi:10.1371/journal.pone.0071449.g001
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interaction of CAV1 with EphA2 in the presence of the ligand
activates AKT signaling to promote bFGF expression. To further
demonstrate the implication of AKT in producing bFGF we
stimulated TC71 cells with ephrin-A1 in the presence of an AKT
inhibitor. Results showed that cells stimulated in the presence of
the AKT inhibitor, although showing stimulation of EphA2
(Figure 6C), did not respond inducing more bFGF transcript
(Figure 6E). These results strongly suggest that, indeed, induction
of bFGF after ephrin-A1 stimulation occurs through activation of
the AKT signaling.
Figure 2. CAV1 silencing results on reduced endothelial cell migration. A. Quantification of endothelial cell growth comparing conditioned
media (CM) from CAV1 knocked-down models versus RPMI without serum as negative control (n = 3). B. Quantification of endothelial cell migration
where CM from RDES and TC71 models was used as chemoattractant for endothelial cells; bars, SD (*P#0.05 n = 3) C. Phospho-FAK
immunofluorescence. Endothelial cells cultured with CM from TC71 CAV1 knocked-down model, showing a decrease on phospho-FAK sprouts. Scale
bar, 20 mm. D. FAK expression was analyzed in PAEC cells grown in CM from the TC71 model. Blot shows higher expression of 35 kd cleaved FAK
form in cells grown with TC71 control CM than with TC71 Sh CM.
doi:10.1371/journal.pone.0071449.g002
CAV1-EphA2 Signaling and Angiogenesis in EWS
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Promotion of Angiogenesis through EphA2 is Kinase-
dependent
Forward EphA2 signaling is mainly kinase-dependent. None-
theless, Eph receptors are nonclassical receptor tyrosine kinases
because, besides kinase-dependent signaling, ligation of certain
members of the Eph family can also trigger kinase-independent
responses [19]. Given that CAV1 silencing affected tyrosine
phosphorylation of EphA2, we asked whether disrupting EphA2
kinase-dependent activities by stably transfecting a dominant-
negative construct of EphA2 (EphA2-kd) into RDES and TC71
cells would recapitulate the anti-angiogenic effects derived from
CAV1 silencing. Similar to CAV1 knocked down cells EphA2-kd
cells in both models showed a clear decrease in constitutive EphA2
phosphorylation (Figure 7A) and a displacement of the receptor
Figure 3. CAV1 silencing results in reduced bFGF transcription and secretion. A. bFGF expression was analyzed in CAV1 knocked-down
models showing that bFGF expression was affected constantly in all models. The graph shows the quantification of the OD volume determined from
the intensity of the bands from the RT-PCR images showing the statistically significant reduction in bFGF in CAV1 knocked-down cells; bars, SD
(*P#0.05 n = 3) B. Immunoblot showing bFGF reduction in the TC71 model either in total protein extract or CM. Actin blot and ponceau staining was
used as loading control. Quantitative data measuring relative intensity of the bands is indicated below each lane (n = 3) C. Quantification of
endothelial cell migration. CM was used as chemoattractant for endothelial cells. A neutralizing antibody -N. Ab- (2.5 mg/ml and 5 mg/ml) and a
recombinant protein -R. Prot- (10 ng/ml); bars, SD (*P,0.002– when compared with parental CM – and *P = 0.0005– when compared with clone n = 3)
were used to block and promote migration respectively. RPMI media alone was used as negative control.
doi:10.1371/journal.pone.0071449.g003
CAV1-EphA2 Signaling and Angiogenesis in EWS
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from the membrane to the cytosolic fraction of RDES cells
(Figure 7B). Also, conditioned media from RDES EphA2-kd cells
showed significant reduced capability to promote migration of
endothelial cells (P#0.05) (Figure 7C). Tumor growth reduction
was significant in the RDES EphA2-kd model (P#0.05) and
considerable (about 50%) although not reaching significance
Figure 4. EphA2 receptor is expressed in EWS cells and is constitutively activated. A. Immunoblot of EphA2 in EWS cell lines B.
Immunoblot of EphA2 in CAV1 knocked-down models showing a slight reduction of EphA2 expression in knocked-down cells when compared with
parental and control cells. C. Immunoprecipitation of EphA2 blotted with phosphotyrosine and immunoprecipitation of phosphotyrosine blotted
with EphA2 confirming its constitutive activation. D. Immunofluorescence of the RDES model showing EphA2 redistribution in cell cytoplasm as a
consequence of CAV1 silencing. DAPI was used to identify the nucleus. Scale bar, 10 mm.
doi:10.1371/journal.pone.0071449.g004
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(P = 0.19) in the TC71 EphA2-kd model (Figure 7D). Histological
analysis of tumor sections however, showed considerable higher
amounts of necrosis in EphA2-kd cells from both models (Figure
S6). Accordingly, MVD reduction was significant in the RDES
model (P#0.05) and considerably lower (40%) in the TC71 model
(Figure 7E). Lastly, after ephrin stimulation EphA2-kd cells from
the TC71 model neither showed AKT activation (Figure 7F) nor
overexpression of bFGF (Figure 7G) suggesting that EphA2 kinase-
dependent signaling through activation of AKT is necessary for
bFGF overexpression and promotion of angiogenesis in EWS
tumors.
Discussion
Like all solid tumors, EWS require a viable vascular supply for
tumor cells to grow beyond the limits of oxygen and nutrient
diffusion into tissues [14]. EWS basically rely on a combination of
angiogenesis and vasculogenesis [20]. Apart from what is known
about the role of vasculogenesis in EWS vascular tumor blood
supply [20], little is known about the regulation of angiogenesis
sprouting. As shown previously, CAV1 silencing in EWS cells
impairs tumor growth in nude mice [2]. Because CAV1 has been
shown to contribute to the progress of angiogenesis in different
tumor entities [21,22], we sought to determine whether the
Figure 5. CAV1 interacts with EphA2 receptor. A. Co-immunoprecipitation of CAV1 and EphA2 showing their interaction. B. Co-
immunofluorescence of CAV1 and EphA2 showing co-localization in cell membrane in RDES cells. DAPI was used to identify the nucleus. The grade of
co-localization was measured by the Pearson’s correlation coefficient (PCC) PCC = 0.6560.009. Scale bar, 10 mm.
doi:10.1371/journal.pone.0071449.g005
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impairment of tumor growth correlated with impaired angiogen-
esis as a consequence of CAV1 silencing and the mechanisms
involved. We established three new models of low CAV1
expression in EWS cells. In all three, reduction of tumor growth
correlated with a significant decrease of MVD. To our knowledge,
this is the first study demonstrating a direct effect on tumor
angiogenesis by knocking down CAV1 in tumor cells.
In order to determine the effects of EWS cell CAV1 silencing on
endothelial cells, we used CM from the models and compared,
in vitro, the proliferative and migratory capacity of endothelial cells.
Figure 6. Stimulation of EphA2 promotes bFGF transcription through activation of AKT. A. Immunoblot showing higher EphA2
phosphorylation in response to ephrin-A1 stimulation in control cells compared with CAV1 knocked down starved cells. EphA2 blotting was used as
control. B. Immunoblot showing activation of AKT in control cells and RT-PCR showing higher bFGF transcription after ephrin-A1 stimulation. No
significant changes on ERK1/2 phosphorylation are shown. Quantitative data measuring relative intensity of the bands is indicated below each lane
for the phospho-AKTs western analysis (n = 5) C. Immunoblot showing blockage of AKT activation in TC71 cells stimulated with ephrin-A1 in the
presence of an AKT inhibitor (5 mM). Quantitative data measuring relative intensity of the bands is indicated below each lane (n = 5). D and E. By RT-
PCR bFGF transcript changes are shown. Quantitative data measuring relative intensity of the bands is indicated below each lane (n = 3).
doi:10.1371/journal.pone.0071449.g006
Figure 7. Dominant negative EphA2 recapitulates CAV1 silencing effects on angiogenesis. A. Phosphotyrosine immunoblot confirming
the dominant negative effects of EphA2-Kd vector in RDES and TC71 cells (RD/CMV and TC/CMV states for empty-vector transfected cells). EphA2
blotting was used as control. B. Immunofluorescence of EphA2 showing redistribution in cell cytoplasm as a consequence of EphA2-Kd transfection.
Scale bar, 10 mm. C. Quantification of transwell cell migration, CM from the EphA2-Kd models was used as chemoattractant for endothelial cells; bars,
SD (*P#0.05 n = 3); vertical bars represent mean percentage of migrated endothelial cells relative to control. D. Mice xenograft volumes comparing
tumors of 2 EphA2-Kd cell clones (n = 5 for each clone) relative to grouped controls (parental n = 5; empty vector n = 5); vertical bars represent mean
percentage of tumor volumes relative to controls; bars, SD (*P#0.05) E. MVD comparing both EphA2-Kd models and showing a reduction of blood
vessels in selected clones relative to controls; bars, SD (*P#0.05) F. Immunoblot of the TC71 model (Control and EphA2-Kd clone) stimulated with
ephrin-A1 showing no changes on the ERK1/2 pathway and activation of AKT. Quantitative data measuring relative intensity of the bands is indicated
below each lane for the phospho-AKTs western analysis (n = 5) G. RT-PCR showing increased expression of bFGF in control cells compared to EphA2-
Kd cells after EphA2 stimulation. Quantitative data measuring relative intensity of the bands is indicated below each lane (n = 3).
doi:10.1371/journal.pone.0071449.g007
CAV1-EphA2 Signaling and Angiogenesis in EWS
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Results showed that CM from knocked down cells had a reduced
capability to induce endothelial cell migration without affecting
proliferation. Activation of FAK has been shown during endothe-
lial cell migration [23,24]. Moreover, FAK proteolysis has been
demonstrated to correlate with adhesion dynamics and migration
[25]. Accordingly, activation and higher proteolysis of FAK was
observed only in endothelial cells in the presence of control
conditioned media. These results suggested that CAV1 silencing
negatively affected the expression or production of factors related
to endothelial cell migration.
EWS cells express a variety of pro-angiogenic factors [14,20,26].
Analysis of the levels of a group of pro-angiogenic factors released
by tumor cells showed that only the expression of the bFGF gene
was reduced by CAV1 silencing. In agreement with our results,
VEGF has been shown to be expressed in EWS cells [27] and to
promote vasculogenesis. Furthermore, VEGF has been postulated
to be an indirect target of EWS/FLI1 [28]. VEGF released from
tumor cells is the most important pro-angiogenic factor that
stimulates both sprouting and proliferation of endothelial cells.
Nevertheless, other factors such as PDGF, FGF and PlGF are also
important [29]. One of the most important roles of bFGF is
promoting endothelial cell migration [30,31]. This would explain
why the major effect observed in endothelial cells as a consequence
of CAV1 silencing in tumor cells was reduced migration.
Moreover, experiments performed with exogenous bFGF and its
neutralizing antibody further supported the importance of bFGF
in endothelial cell migration. Importantly, increases in bFGF
expression can enhance tumor angiogenesis and promote tumor
growth [32]. However, as a complicated multistep process, tumor-
associated angiogenesis is implicated in the extensive interplay
among cells, soluble factors, and extracellular matrix (ECM)
components. Moreover, the ‘‘angiogenic switch’’ via the change of
the local balance of pro- and anti-angiogenic factors, is critical for
the initiation of tumor angiogenesis [33]. Thus, we cannot rule out
the possibility that CAV1 also plays an important role in the
regulation of other complicated processes in angiogenesis.
The role of eph receptors and ephrins in tumor angiogenesis is
well acknowledged [34]. Expression of several eph receptor and
ephrin family members in EWS cells has been shown previously
[35]. Ephrin A1, EphA2, EphB3 and EphB4 expression was
observed in our panel of EWS cell lines. However, only EphA2
was seen in tumor samples. This is of relevance because ours is the
first study demonstrating the expression of EphA2 protein in EWS
patient samples. Eph receptors contain a caveolin-binding motif
within their kinase domain (WSYGIVMW for EphA2). Moreover,
interaction of EphA2 with CAV1 has been shown as key for
proper signaling and membrane targeting of the receptor [18]. By
a combination of immunoprecipitation and confocal microscopy
assays we show that, indeed in EWS cells CAV1 interacts with
EphA2. Furthermore and in agreement with previous results [18],
CAV1 silencing resulted in delocalization of the receptor and
moderate decrease in its expression suggesting some sort of
degradation after losing its targeting to the membrane. Degrada-
tion of eph receptors, as for other receptors, has been shown after
endocytosis following activation [36]. Nonetheless, this might be
not the case because constitutive tyrosine phosphorylation of
EphA2 in EWS cells is lost after CAV1 silencing. However,
whether this mere loss of protein depends on degradation or not,
remains to be further determined.
In order to establish a relationship between EphA2 activation
and bFGF expression we decided to perform EphA2 stimulation
assays with ephrin-A1. As expected [18], CAV1 knocked down
cells responded less efficiently to ephrin-A1 stimulation than
control cells. EphA2 signaling has been repeatedly shown to occur
through MAPKs [37,38]. AKT signaling has also been shown to
be activated as a consequence of EphA2 stimulation in several cell
lines [39]. In our model, stimulation of EphA2 by its ligand
resulted in an increase of AKT phosphorylation and higher
transcription of bFGF. However, no activation of MAPK signaling
was observed. Lack of increased bFGF transcription in stimulated
cells with the presence of an AKT inhibitor, that inhibits AKT
phosphorylation without affecting PI3K, further confirmed the
involvement of AKT signaling in bFGF transcription in response
to EphA2 stimulation.
EphA2 kinase is frequently up-regulated in several different
types of cancer [40]. It is not clear whether EphA2 phosphory-
lation or its overexpression plays a role in tumor progression. In
fact, simply overexpression of the receptor likely will lead to Eph
kinase-independent responses [41]. Because CAV1 silencing
affected primarily EphA2 tyrosine phosphorylation we focused
on kinase-dependent activities. In agreement with studies per-
formed in prostate cancer cells [41], introduction of a dominant
negative form of EphA2 into TC71 and RDES recapitulated most
of the effects induced by CAV1 silencing. Thus, we observed a
decrease of constitutive EphA2 phosphorylation and the conse-
quent displacement of EphA2 receptor from the membrane to the
cytosolic fraction in RDES cells. Conditioned media from RDES
EphA2-kd cells showed reduced capability to promote migration
of endothelial cells. Furthermore, tumor growth reduction was
observed in both models showing a great degree of necrosis.
Accordingly, MVD reduction was also observed in both models.
Lastly, after ephrin stimulation EphA2-kd cells from the TC71
model neither showed AKT activation nor overexpression of
bFGF. Overall, our results underscore the critical role of EphA2
kinase-dependent activity promoting EWS angiogenesis.
CAV1 silencing in EWS cells results in loss of tumorigenicity,
sensitization to chemotherapy and reduced migratory and invasive
capabilities [42]. EphA2 appears to play a role in tumorigenesis in
its non-phosphorylated state and possesses ligand-independent
kinase activity in vitro [43,44]. We did not observe significant
changes in the malignant phenotype of cells transfected with the
EphA2 dominant-negative construct (data not shown). However,
we cannot discard the possibility that in EWS cells EphA2 might
play a critical role in their tumorigenic phenotype independently
of its kinase activity. Current studies in the laboratory are
addressing this issue. Taken together, our results strongly suggest
that the axis EphA2-CAV1 cause activation of AKT signaling to
produce bFGF, promoting tumor induced endothelial cell
migration and favoring EWS angiogenesis.
Materials and Methods
Ethics Statement
Animal care and procedures were followed according to the
Institutional Guidelines for the Care and Use of Laboratory
Animals. Ethics approval was provided by the locally appointed
ethics committee from the Biomedical Research Institut (IDI-
BELL), Barcelona, Spain.
Cell Culture, Stable Transfections and Stimulation Assays
A673, TC252 and STAET1 cell lines (gifts from Dr. Heinrik
Kovar, Children’s Cancer Research Institute, Kinderspitalgasse,
Vienna, Austria [45]); RH1 cell line (gift from Dr. Peter
Houghton, The Research Institute at Nationwide Children’s
Hospital, Columbus, Ohio [46]); RDES, TC71 and SKES1 cell
lines (bought from DSMZ, Leibniz Institute DSMZ-German
Collection of Microorganisms and Cell Cultures, Braunschweig,
Germany); and A4573 cell line (gift from Dr. Santiago Ramo´n y
CAV1-EphA2 Signaling and Angiogenesis in EWS
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Cajal, Departament d’Anatomia Patolo`gica, Hospital Universitari
Vall d’Hebron-Universitat Auto`noma de Barcelona, Barcelona,
Spain [2]), all EWS cells, were cultured in RPMI 1640 (Invitrogen)
supplemented with 10% heat-inactivated fetal bovine serum
(Invitrogen). PAEC cells –Porcine Aortic Endothelial Cells– (gift
from Dr. Cristina Costa, Institut d’Investigacio´ Biome`dica de
Bellvitge, l’Hospitalet de Llobregat, Barcelona, Spain [47]) were
cultured in RPMI 1640 (Invitrogen) supplemented with 10% heat-
inactivated bovine serum (Invitrogen) and endothelial mitogen
(50 mg/l; Biomedical Technologies Inc.). All cell lines were
incubated at 37uC in a humidified atmosphere of 5% CO2 in
air. Exponentially growing cells within two sequential passages
were used for all experiments. Cells were transfected using Fugene
Transfection Reagent (Roche) or Lipofectamine 2000 (Invitrogen)
following the protocols of the manufacturer. Transfected cells were
selected with neomycin [0.4 mg/ml or 0.8 mg/ml, ShCAV1
[2,16] and EphA2kd [41] (kindly gifted by Dr. Paola Chiarugi,
University of Florence, Florence, Italy), respectively; Invitrogen]
for 14 days, and antibiotic-resistant pools and individual colonies
were isolated for further analysis and maintained in the presence of
neomycin (0.4 mg/ml or 0.8 mg/ml). For studies using soluble
ephrinA1, cells were stimulated with 5 mg/ml IgG/Fc or
ephrinA1-Fc (R&D Systems) for 20 min. When needed AKT
inhibitor IV (Merck Millipore) was used at a concentration of
5 mM.
Immunoprecipitacion and Western Blot Analysis
EWS cells were lysed with radioimmunoprecipitation assay
buffer (RIPA Buffer, Thermo Scientific) containing protease
inhibitors (Complete, Mini; Protease Inhibitor Cocktail Tablets,
Roche) and phosphatase inhibitors (PhosStop, Phosphatase
Inhibitor Cocktail Tablets, Roche) and centrifuged at 13,0006g,
at 4uC, for 30 minutes. The protein content of the supernatants
was determined with the BCA assay system (Pierce). For
immunoprecipitation, cells lysis was made using immunoprecip-
itation buffer with 50 mM Tris-HCl (pH 7.6), 150 mM NaCl, 1%
NP-40 and containing protease and phosphatase inhibitors.
Magnetic beads coated with Protein G (Millipore) were incubated
following manufacturer’s protocol with previously incubated
500 mg protein samples with its respective antibody (CAV1
#610059 from BD Biosciences; EcK/EphA2 #05-480 and
Phosphotyrosine #05-321 from Millipore, normal mouse IgG
#sc-2025 and normal rabbit IgG #sc-2027 from Santa Cruz
Biotechnology). After immunoprecipitation, beads were resus-
pended for denaturating elution in 30 ml of sample buffer. Lysate
aliquots (50 mg) and immunoprecipitations were resolved by 8, 10
or 15% SDS-PAGE (depending on the size of the protein that was
analyzed) and transferred onto nitrocellulose membranes (0.2 mm,
Bio-Rad). After blocking with 5% skimmed milk in Dulbecco’s
PBS (DPBS) containing 0.1% Tween20 at room temperature for 1
hour, membranes were incubated overnight at 4uC with the
appropriate primary antibody (CAV1; EcK/EphA2, FGF/ba-
sicFGF #05-118 and Phosphotyrosine from Millipore; FAK
#3285, Akt #9272, Phospho-Akt Ser473 #4060 and Phospho-
Akt-Thr308 #9275 from Cell Signaling Technology). Blots were
then incubated at room temperature for 1 hour with a horseradish
peroxidase-conjugated secondary antibody (goat anti-rabbit and
goat anti-mouse) and the peroxidase activity was detected by
enhanced chemiluminescence (Pierce) following the instructions of
the manufacturer. Immunodetection of b-actin (#ab49900 from
Abcam) was used as a loading reference.
Proliferation Assay
A density of 56104 cells per well was seeded on 12-well-plate
overnight in complete culture medium and then treated with
RPMI alone (Negative control) or CM from TC71 and RDES
models for a 3-day incubation. The cell numbers were measured
every 24 hours by the trypan blue exclusion assay.
Transwell Migration Assay
PAEC cells (2.06104) in 100 mL of serum-free medium were
added to the top chamber of 8 mm Costar polycarbonate
membrane transwell (Transwell Permeable Supports, Corning),
while 500 mL of CM from EWS cell models was added to the
bottom chamber. CM was obtained by culturing cells for 48 hours
in fresh RPMI media without serum. After this time media was
centrifuged and filtered to avoid any suspended cells. After
allowing migration for various times (37uC, 100% humidity, 5%
CO2 in air), cells on the upper membrane surface were removed
and migrant cells on the membrane underside were fixed using
70% ethanol, stained using 0.1% crystal violet solution (Sigma-
Aldrich), and visualized and counted under the microscope.
Neutralizing antibody against bFGF (Anti-FGF2/basic FGF #05-
117) and human recombinant FGF-2/basic (FGF2 #01-106) were
from Millipore and were used at mentioned concentrations. Data
were presented as the average number of migrating cells in 5 high-
power fields (x200). Each experiment was done in triplicate, and
then the data were averaged for statistical analysis.
In vivo Studies
Experiments to evaluate the tumor development of CAV1
knocked down models were carried out using immunodeficient
female (5–6 weeks old) athymic nude mice purchased from Harlan
Laboratories. Mice were injected subcutaneously (s.c) into the right
posterior flank with 36106 RDES (n= 20), TC71 (n= 20) and
SKES1 (n= 20) low CAV1 models and RDES (n= 10) and TC71
(n= 10) EphA2-kd models in 100 ml of RPMI (Invitrogen). Once
tumors reached a mean volume of about 1 cm3 (21 days), mice
were euthanized. Tumors were fixed in formaldehyde at 4% and
embedded in paraffin. Tumor volumes were calculated by the
formula V= (1/2) a6b2, where a is the longest tumor axis, and b is
the shortest tumor axis. Data are given as mean 6 SD. Statistical
analysis was done by an unpaired Student’s t test.
Immunohistochemistry and Immunofluorescence
Immunohistochemical techniques were done essentially as
previously described [2]. Expression of CAV1 in human EWS
and xenografts was analyzed using a rabbit polyclonal antibody
(CAV1 #610059). Microvascular density was analyzed using a
polyclonal antibody for CD31 (Platelet Endothelial Cell Adhesion
Molecule-1: PECAM-1) from Abcam (#ab28364). Data were
presented as the average number of positive vessels in the whole
section of the tumor from all samples comparing the model.
EphA2 expression was analyzed using a polyclonal antibody for
EphA2 (EphA2 IHC Antibody from Bethyl Laboratories #IHC-
00427). For immunofluorescence, EWS cells were cultured in
sterile slides (Millicell EZ slide from Millipore) for 24 hours, fixed
with 4% formaldehyde for 30 minutes, washed thrice in
Dulbecco’s PBS (DPBS), permeabilized in 0.1% Triton X-100
(Sigma) for 2 minutes, blocked for 1 hour in blocking buffer (10%
goat serum in DPBS) and incubated with primary antibodies
overnight. Cells were then washed thrice in DPBS for 5 minutes
each followed by a 1 hour incubation with secondary antibodies
(Alexa Fluor 488 goat anti-mouse and Alexa Fluor 594 goat anti-
rabbit; Invitrogen). Then, cells were washed twice in DPBS for 10
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minutes and twice in distilled water for 10 minutes, and mounted
in ProLong Gold antifade reagent with 49,69-diamidino-2-
phenylindole (Invitrogen). Photographs were taken with a Leica
TCS SP5 spectral confocal microscope (argon, 405 diode and
DPSS561 lasers) using a lambda blue 6361.35 numerical aperture
oil objective. Images were analyzed with the MacBiophotonics
Program. CAV1 and EphA2 expression in EWS cells was
analyzed by using the same specific antibodies. Expression of
Phospho-FAK was detected in PAEC cells using a polyclonal
antibody for Phospho-FAK –Tyr397– #3283 from Cell Signal-
ling. PAEC cells, serum depleted for other 16 hours were cultured
in conditioned media from the TC71/ShCAV1 model for 48
hours.
Reverse Transcription-PCR (RT-PCR)
Total RNA (2 mg), extracted using the Total RNA Isolation Kit
(NucleoSpin RNA II, Macherey-Nagel), was used for cDNA
synthesis with SuperScript II Reverse Transcriptase (Invitrogen).
Primers 59-CGGAATGAGGACTACACCATACATGTG-
CAGC-39 (forward) and 59-AAGCAGCGGTCTT-
CATGCTGGTGGATGGGTT-39 (reverse) were used for ampli-
fication of Ephrin-A1 (326 bp); and for b-Actin (432 bp), 59-
CGGGACCTGACTGACTACCTC-39 (forward) and
CTTCATTGTGCTGGGTGC (reverse). Amplification of
Ephrin-A1 was adjusted at an annealing temperature of 58uC and
59.5uC for b-Actin. Amplifications of bFGF, PDGF-A, PDGF-B,MK,
TGFB and VEGF were carried out using specific primers (Table
S1). For each set of primers, the number of cycles was adjusted so
that the reaction end points fell within the exponential phase of
product amplification, thus providing a semi-quantitative estimate
of relative mRNA abundance. RT-PCR determinations were
carried out thrice for each relevant transcript. Primers were from
Invitrogen.
Tissue Samples
28 tumor samples were procured from the archives of the
Tumor banks of St. Joan de Deu Hospital (13 patients) and Centro
de Investigacio´n del Cancer-IBMCC (15 patients) Pathology
Departments and referring institutions. All tumor samples were
fixed in formalin, embedded in paraffin, and had not undergone
decalcification. Associated clinical data were available only for the
St. Joan de Deu Hospital. Because all patients showed EphA2
expression no clinical correlations could be made.
Statistical Analysis
Data were analyzed for statistical significance using Student’s t
test. In the case of confocal images pair wise correlations were
evaluated by the two-tailed Pearson-test, measuring the strength of
the association between two variables. For immunoblot and RT-
PCR experiments relative expression of each gene to the reference
gene (Actin) was calculated measuring each band area after
subtracting background using Image J software (IJ 1.46r, NIH,
USA). Unless otherwise stated, experiments were performed thrice
and P#0.05 was regarded as significant.
Supporting Information
Figure S1 bFGF expression in EWS cell lines. Several
growth factors (PDGF-A, PDGF-B, MK, TGFB1, VEGF and bFGF)
were analyzed by RT-PCR.
(TIF)
Figure S2 CAV1 silencing reduces bFGF expression.
Several growth factors (PDGF-A, PDGF-B, MK, TGFB1, VEGF and
bFGF) were analyzed by RT-PCR in CAV1 knocked down
models. Results showed that bFGF was the only one reduced
constantly in all models.
(TIF)
Figure S3 EphA2 protein expression in human tumor
samples. Immunohistochemical analysis of positive EWS
samples demonstrating the presence of EphA2 (left panel) and
the absence of other members of the family (EphB3 and EphB4).
EphA2 expression was positive in all tumors and the pattern of
expression was observed in both membrane and cytoplasm. Scale
bar, 50 mm.
(TIF)
Figure S4 RT-PCR for ephrin-A1. EphA2 most common
ligand, ephrin-A1, is expressed in all EWS cells tested.
(TIF)
Figure S5 Co-expression of CAV1 and EphA2 proteins in
mouse xenografts samples. Co-Immunofluorescence of
CAV1 and EphA2 showing co-localization in cell membrane in
paraffin embedded tissue from mouse xenograft. Scale bar, 20 mm.
(TIF)
Figure S6 Hematoxylin and Eosin (H&E) staining in EphA2-Kd
paraffin-embedded xenografts from RDES and TC71 models
showing a decrease in tumor volume and an increase of necrosis (*)
in EphA2-Kd tumors. Scale bar, 50 mm.
(TIF)
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